PD14-05 FACTORS ASSOCIATED WITH DISCONTINUATION OF ONABOTULINUM TOXIN-A THERAPY FOR OVERACTIVE BLADDER IN A DIVERSE URBAN POPULATION

Abstract

You have accessJournal of UrologyCME1 Apr 2023PD14-05 FACTORS ASSOCIATED WITH DISCONTINUATION OF ONABOTULINUM TOXIN-A THERAPY FOR OVERACTIVE BLADDER IN A DIVERSE URBAN POPULATION Arshia Aalami Harandi, Mariel Liebeskind, and Nitya Abraham Arshia Aalami HarandiArshia Aalami Harandi More articles by this author , Mariel LiebeskindMariel Liebeskind More articles by this author , and Nitya AbrahamNitya Abraham More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003261.05AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Although overactive bladder (OAB) is a common condition affecting 16% of Americans, few patients continue second-line and third-line treatment. This study sought to investigate factors associated with discontinuation of intravesical Onabotulinom Toxin-A (BTX-A) injections among a diverse urban population. METHODS: This was a retrospective review of patients who underwent BTX-A injection for OAB at a university hospital between November 2015 and December 2021. Patients were considered to have discontinued BTX-A therapy if they only received one treatment and it had been more than 1 year since last date of service. Patients with neurogenic OAB were excluded. Patient demographics, past medical history, symptoms, and post-operative outcomes were compared between groups with Chi-squared, Student’s t-test, or Fisher’s exact test. RESULTS: BTX-A injections were administered to 272 patients who met study criteria of which 114 (41.9%) had discontinued BTX-A therapy. Our cohort included 235 (86%) women and had a mean age of 61.5 and mean BMI of 30.8. Patients discontinuing BTX-A therapy had a higher median income ($59K vs. $50K, p<.01) and were more likely to have reported nocturia (61.7% vs. 39.3%, p<.001). Patients who discontinued were less likely to have reported subjective improvement of symptoms at their first post-procedure visit (73.0% vs. 83.6%, p<.05). Similarly, patients who developed post-operative urinary retention were more likely to discontinue BTX-A therapy (17% retention in discontinuation group vs. 8% in those who continued p<.05). There were no associations between discontinuation and Race/Ethnicity, distance to clinic, smoking history, or post-operative urinary tract infections. CONCLUSIONS: Adverse outcome after BTX-A injection, such as post-operative urinary retention, is associated with discontinuation of therapy, whereas subjective improvement in symptoms is associated with continuation of therapy. Given the large proportion (>40%) of patients who discontinued BTX-A treatment, further research is needed to identify barriers to continuation of care. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e414 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Arshia Aalami Harandi More articles by this author Mariel Liebeskind More articles by this author Nitya Abraham More articles by this author Expand All Advertisement PDF downloadLoading ...